ERBB2 and breast carcinoma: The SOPHIA trial showed no significant overall survival (OS) difference between margetuximab and trastuzumab in HER2-positive advanced breast cancer (21.6 vs. 21.9 months; HR 0.95); safety profiles were similar [34].